Xlife Sciences AG<\/a> (XLS DE), inflamed pharma GmbH
\nhas developed a revolutionary and holistic therapeutic approach to treat both
\nSARS-CoV-2 and flu viruses. The patented active substance ProcCluster<\/b>(R)
\nreduces the viral load by 90% and acts against infection-related inflammatory
\nprocesses without developing a resistance. It is already used on humans.<\/b><\/p>\nThe active pharmaceutical ingredient ProcCluster(R) developed by inflamed pharma GmbH is membrane permeable and is based on the active ingredient procaine. It acts both locally as well as systemically and is characterized by a wide range of applications in inflammatory diseases. ProcCluster(R) is already used for various prescription drugs for humans. In various case studies, renowned medical doctors have now been able to successfully demonstrate the effectiveness in the treatment of Covid-19 and Long-Covid patients. In studies with various cell lines, especially lung cells, the active ingredient was able to reduce the viral load by 90% in an early phase and effectively inhibit inflammation in a later phase. These effects can be transferred to other RNA viruses.<\/p>\n
\n
<\/p>\n
Oliver R. Baumann, CEO of Xlife Sciences AG, comments: “ProcCluster(R)
\nhas enormous market potential because, in contrast to other active ingredients,
\nboth the inflammatory processes and the viral load in the body are
\nsignificantly reduced. This means that it can be used at different points in
\ntime during the course of the Covid-19 disease”. It is of inestimable
\nvalue that this active ingredient is already produced by inflamed pharma GmbH
\nin high quality at low cost. “Another key advantage compared to vaccines
\nand antibodies is that ProcCluster(R) does not lead to resistance development
\nand can also be used against virus mutants”, continues Baumann. In
\naddition, ProcCluster(R) has a stimulating effect on the microcirculation,
\nwhich is particularly important for Long-Covid patients. So far, no negative
\nside effects have been observed either.<\/p>\n
According to the management of Xlife, they are already in various discussions with possible industrial partners in order to have ProcCluster(R) industrially manufactured. The aim is for the active ingredient to be licensed out as quickly as possible.<\/p>\n
The issuer is solely responsible for the content of this announcement.<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"First available holistic medical drug to treat Covid-19 and flu viruses ZURICH, SWITZERLAND – EQS Newswire – 10 June 2021 –\u00a0As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH
has developed a revolutionary and holistic therapeutic approach to treat both
SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R)
reduces the …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/15419"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=15419"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/15419\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=15419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=15419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=15419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}